Impact of the KEYNOTE-045 Study Comparing Pembrolizumab and Chemotherapy in Bladder Cancer

November 17, 2016
Joaquim Bellmunt, MD, PhD

Joaquim Bellmunt, MD, PhD, attending physician of Solid Tumor Oncology at Dana-Farber Cancer Institute, discusses the impact of the phase III KEYNOTE-045 study, which compared second- or third-line pembrolizumab with investigator-choice chemotherapy as a treatment for patients with metastatic or locally advanced, unresectable urothelial carcinoma. All patients in the study had recurred or progressed following platinum-based chemotherapy.